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Buruli ulcer (BU) is the third most frequent mycobacterial disease in immunocompetent per-
sons after tuberculosis and leprosy. During the last decade, eight weeks of antimicrobial
treatment has become the standard of care. This treatment may be accompanied by tran-
sient clinical deterioration, known as paradoxical reaction. We investigate the incidence and
the risks factors associated with paradoxical reaction in BU.
Methods
The lesion size of participants was assessed by careful palpation and recorded by serial
acetate sheet tracings. For every time point, surface area was compared with the previous
assessment. All patients received antimicrobial treatment for 8 weeks. Serum concentration
of 25-hydroxyvitamin D, the primary indicator of vitamin D status, was determined in duplex
for blood samples at baseline by a radioimmunoassay. We genotyped four polymorphisms
in the SLC11A1 gene, previously associated with susceptibility to BU. For testing the associ-
ation of genetic variants with paradoxical responses, we used a binary logistic regression
analysis with the occurrence of a paradoxical response as the dependent variable.
Results
Paradoxical reaction occurred in 22% of the patients; the reaction was significantly associ-
ated with trunk localization (p = .039 by Χ2), larger lesions (p = .021 by Χ2) and genetic fac-
tors. The polymorphisms 3’UTR TGTG ins/ins (OR 7.19, p < .001) had a higher risk for
developing paradoxical reaction compared to ins/del or del/del polymorphisms.
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Conclusions
Paradoxical reactions are common in BU. They are associated with trunk localization, larger
lesions and polymorphisms in the SLC11A1 gene.
Author Summary
Buruli ulcer is an infectious disease of skin, subcutaneous fat and sometimes bone, mainly
affecting children in West Africa. It is considered as one of the Neglected Tropical Diseases
but the disease occurs also in moderate climates like South East Australia and Japan where
it may also affect adults. Once a patient has started antibiotic treatment, lesions may
increase in size even if the antimicrobial treatment is effective; this is highly confusing for
doctors and patients as they may think that treatment actually fails. The cause of Buruli
ulcer isMycobacterium ulcerans, related to other mycobacteria that cause disease in man,
like leprosy and tuberculosis. Using data from two different studies in West Africa, we
show that these paradoxical reactions are associated with trunk localization and that they
occur more often in larger lesions. The chance to develop these reactions appeared partly
inherited: carrying the homozygous ins/ins genotype of 3’UTR TGTG 285 polymorphism
in the SLC11A1 gene increased the risk of paradoxical reactions. Vitamin D is important
for the immune defense against infections by mycobacteria. Vitamin D blood concentra-
tions were not associated with paradoxical reactions; patients generally did well, and we
did not need corticosteroid immune suppression to overcome these reactions.
Introduction
The neglected tropical disease Buruli ulcer (BU) is the third most frequent mycobacterial dis-
ease in immunocompetent persons after tuberculosis and leprosy [1–2]. It is caused byMyco-
bacterium ulcerans. Central to the pathogenesis is the immunosuppressant and necrosis
inducing toxin mycolactone.
During the last decade, an antibiotic regimen of eight weeks of streptomycin and rifampicin
was introduced [3,4]. Earlier studies reported the success of this antimicrobial treatment with
or without surgery [5–7]. A clinical trial showed that antimicrobial treatment was highly effec-
tive in patients with small lesions (cross-sectional diameter< 10 cm), of which 96% healed
without surgery [8].
However, during or after antibiotic treatment the BU lesions may worsen. This could be
caused by treatment failure [9–11], but might also be due to an inflammatory response caused
by treatment-induced recovery of the immune system, i.e. a paradoxical reaction. Paradoxical
reactions have been described in tuberculosis and in leprosy [12,13]. Recent studies have recog-
nized the existence of paradoxical reactions in BU [11,14]. In Australia, one in five BU patients
appear to have a paradoxical reaction. Most cases occurred between three and ten weeks after
the start of treatment [9]. In a trial in Ghana, most of the cases with a paradoxical reaction
(>30%) were reported at week eight after the beginning of antimicrobial treatment [15]. The
diagnosis of paradoxical response is difficult; no serological markers have been identified to dif-
ferentiate paradoxical reactions from treatment failure [15]. Paradoxical reactions can be
defined clinically by worsening of existing lesions, or the appearance of new lesions, and histo-
logically by the appearance of intense inflammation in lesions [9]. Importantly, in most areas
endemic for BU, histology is not available. In Africa, very few studies have addressed
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paradoxical reactions in BU [10,14] as well as its risk factors. In Australia, edematous lesions,
use of amikacin and age above sixty years old were strongly associated with paradoxical reac-
tions. In addition to sociodemographic and clinical features, we suggest genetic factors may
influence the occurrence of paradoxical reactions as well. As paradoxical reactions are hypothe-
sized to reflect an exaggerated immune response, genes involved in the immune response in
infectious diseases might play a role. For BU, a polymorphism in the innate immune SLC11A1
gene (formerly known as NRAMP1) was previously found to be associated with increased sus-
ceptibility to BU [16]. Furthermore it has been shown that 1,25(OH)2D3 suppresses the Th1
response by down-regulating the production of pro-inflammatory cytokines [17–19]. So it is
possible that polymorphisms in SLC11A1 gene as well as vitamin D are also related to paradox-
ical reactions.
In West Africa, most of the patients are below age 15 [20] and amikacin is not used to treat
BU but very few patients receive antimicrobial treatment without streptomycin, the parent
aminoglycoside drug. As the patient demographics and treatment regimen in West-Africa are
widely different from that of Australia, it is important to look at the risk factors for developing
paradoxical reactions in BU in this region. In Ghana, paradoxical reactions were described in
patients withM. ulcerans infection with early lesions (duration< 6 months), limited to 10 cm
cross-sectional diameter [14]; large lesions that are common in west Africa were not included
in that study. Our study focuses on the risk factors associated with paradoxical reactions in
patients with both small and large BU lesions, during and after antimicrobial treatment, and
examines the influence of genetic factors as well.
Methods
Study population
In the present study, we included participants of two randomized clinical trials in Ghana and
Benin. The BURULICO drug trial with patients enrolled between 2006–2008, was a random-
ized controlled trial for the treatment of early (duration less than 6 months), limited (cross-sec-
tional diameter, 10 cm)M. ulcerans infection [clintrials NCT00321178]. In this trial, patients
were randomized to receive either 8 weeks of streptomycin and rifampicin or 4 weeks of strep-
tomycin and rifampicin followed by 4 weeks of clarithromycin and rifampicin. Participants in
this study that had their BU lesions healed at time point 52 weeks after initiation of antimicro-
bial treatment were earlier studied for possible paradoxical reactions [14]. The second trial is a
randomized trial on timing of the decision on surgical intervention for BU patients treated
with rifampicin and streptomycin [clintrials NCT01432925]. All included patients (2011–
2015) had confirmedM. ulcerans infection by direct microscopy following acid-fast staining or
Polymerase Chain Reaction (PCR), and all received 8 weeks of antimicrobial therapy with
rifampicin and streptomycin. For both trials, patients who were pregnant, children below five
years old, patients not compliant with the antibiotic therapy, and patients with osteomyelitis,
were excluded from the study. For the current study population, 150 of 241 participants of the
BURULICO study, and 91 of the Burulitime study contributed (S1 Dataset).
Study design
For all patients, we recorded demographics and clinical data from the trial databases. In addi-
tion, we recorded the progression of the size of the lesion size by measurement at regular inter-
vals. For both trials, measurements were available for the first 12 weeks at two-week intervals.
In the BURULICO trial, lesions were measured at 14, 21, 27 weeks after start of treatment, and
for the timing of surgical intervention trial, measurements were available at 16, 20, and 28
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weeks after starting treatment. For analyses, the measurements at 14 and 16 weeks, at 21 and
20 weeks, and 27 and 28 weeks were considered to be equivalent time points.
Method of measurement
Lesion size. Lesion measurement included the indurated area around the visible skin
defect; sloughing of indurated skin is an expected clinical course and does not per se constitute
a paradoxical reaction. This lesion measurement was drawn on an acetate sheet and the surface
area was calculated for every individual lesion at the different time point of the follow up.
Vitamin D serum concentration. Baseline vitamin D serum concentrations were available
for patients participating in the BURULICO trial only. Blood samples in clotted blood tubes
for serum were cooled until centrifuged within 24 hours after collection, then stored at -20°C,
and sent in frozen condition from Ghana to the University Medical Center Groningen, the
Netherlands, until processed. Serum concentration of 25-hydroxyvitamin D, the primary indi-
cator of vitamin D status, was determined in duplex for every sample by a radioimmunoassay
(DiaSorin, Stillwater, MN) [21]. The mean of these two results was used for the analyses. Cur-
rently, there is no international consensus on the optimal level for vitamin D [22]. In healthy
humans, vitamin D adequacy is defined as the presence of 25(OH)D3 at a concentration of 50–
75 nmol/L, levels of 75 nmol/L or greater represent vitamin D sufficiency while the serum levels
of 25–50 nmol/L of circulating 25(OH)D3 are defined as vitamin D insufficiency [23,24].
Genetic assays. Genetic data were obtained from patients participating in the BURULICO
trial. Participants in the trial in Benin on timing on surgical intervention, were not asked for
consent to testing of genetic susceptibility and could therefore not be included. The SLC11A1
gene has been previously associated with susceptibility to BU [16]. We genotyped four poly-
morphisms in the SLC11A1 gene: rs59823161 (3’UTR TGTG ins/del); rs17235409 (D543 G/A);
rs3731865 (INT4 G/C); and a (CA)n microsatellite in the immediate 5’ region of the gene, as
described previously [16]. Normal genotype was designated as having a microsatellite length of
200 base pairs and variant genotypes, having microsatellite lengths of 202 or 204 were pooled
as “other”.
Definition of paradoxical response
We considered an increase in lesion area of more than 5% between two consecutive measure-
ments as a clinically relevant change. We defined a paradoxical reaction as 2 consecutive
increases in lesion size after 1 initial decrease. We additionally performed all analyses (post-
hoc) using a less strict definition of two consecutive increases without an initial decrease.
Statistics
For associations of clinical and patient characteristics with paradoxical responses, we used t-
tests or Mann-Whitney U tests for accordingly and Χ2 tests for categorical variables. For testing
the association of genetic mutations and variants with paradoxical responses, we used a binary
logistic regression analysis with the occurrence of a paradoxical response as the dependent
variable.
Ethics
The protocol was approved by the Committee on Human Research, Publication, and Ethics of
the Kwame Nkrumah University of Science and Technology and the Komfo Anokye Teaching
Hospital, Kumasi (CHRPE/07/01/05), by the Ethical Review Committee of Ghana Health Ser-
vices (GHS-ERC-01/01/06) and by the provisional national ethical review board of the
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Ministry of Health Benin, nr IRB00006860. Written and verbal informed consent or assent was
obtained from all participants aged12 years, and consent from parents, caretakers, or legal
representatives of participants aged18 years. All data were analyzed anonymously.
Results
Patient and clinical characteristics
A total of 241 patients were included, 150 from Ghana, and 91 from Benin; 61% were female.
The mean (SD) age was 16.2 (13.2) years. On presentation, 45% of patients had an ulcer, 23%
had a plaque, and 13% had a nodule; 29% had a WHO category I lesion, 55% a category II
lesion, and 16% a category III lesion. The median (IQR) surface area of the lesion on presenta-
tion was 20.6 (6.6; 43.5) cm2; 49% had a lesion on the lower limb, 43% on the upper limb, and
8% on the trunk.
Paradoxical reactions
Paradoxical reactions, as defined by an initial decrease of the lesion followed by two consecu-
tive increases occurred in 22% of cases. Most paradoxical reactions occurred between weeks 8
and 12 (Fig 1). When using a definition that did only require two consecutive increases without
an initial decrease, 26% of patients had a paradoxical response, and the frequency distribution
of the initiation week of paradoxical reaction did not differ substantially. All cases that had a
paradoxical reaction healed without additional treatment.
Associations with patient and lesion characteristics
Paradoxical reactions were significantly related to the site of lesion (p = .039 by Χ2): 44% of
patients with a lesion on the trunk had a paradoxical response, compared to 24% of patients
with a lesion on the upper limb, and 17% with a lesion on the lower limb.
Paradoxical reactions were also significantly related to WHO category at presentation. Ten
percent of patients with a category I lesion had a paradoxical response, compared to 27%, and
23% of patients with a category II and category III lesion, respectively (p = .021 by Χ2). Para-
doxical reactions were not significantly related to patient age or gender. They were also not
related to the type of lesion, duration of lesion before presentation, or white blood cell count at
presentation (Table 1). For the participants in the BURULICO trial, paradoxical reactions were
not related to treatment arm (8 week streptomycin vs 4 weeks streptomycin followed by 4
weeks clarithromycin). The pulse and temperature at the time of paradoxical response did not
differ from the pulse at presentation by paired samples t-test, and did not differ from the aver-
age pulse and temperature of those not classified as having a paradoxical response at the
respective week. Using the less strict definition, the same pattern of results emerged, where par-
adoxical reactions were significantly related to the site of the lesion (p = .024 by Χ2) and WHO
category at presentation (p = .009 by Χ2), but to none of the other variables.
Associations with vitamin D and polymorphisms in the SLC11A1 gene
Vitamin D deficiency was found in 15% of participants. The mean (SD) vitamin D level was
66.5 (19.1) for the patients who had paradoxical reaction and 68.3 (17.1) for those who did not;
38% of patients with a vitamin D deficiency had a paradoxical reaction, compared to 23% of
patients without a deficiency (p = .134 by Χ2). In the post-hoc analysis using the less strict defi-
nition of a paradoxical response, 33% of patients with a vitamin D deficiency had a paradoxical
reaction, compared to 17% of patients without a deficiency (p = .082 by Χ2).
Genetic Predisposition for Paradoxical Reactions in BU
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31% of patients with a 3’UTR TGTG ins/ins polymorphism had a paradoxical response,
compared to 13% of patients with a ins/del or del/del polymorphism (OR 0.14, 95% CI: 0.05–
0.44). 5’(CA)n microsatellite length, INT4 G/C polymorphism and D543N G/G polymorphism
were not significantly related to paradoxical responses (Table 1). Using the less strict definition
of a paradoxical response in a post-hoc analysis, a similar pattern of results emerged.
Discussion
This is the first prospective study in West Africa addressing risk factors associated with para-
doxical reaction in BU. In our sample, paradoxical reactions were common, and significantly
associated with trunk localization, larger lesions and genetic factors. Currently, there is no stan-
dard definition of paradoxical reactions in BU. Histological aspects [9] suggested from Austra-
lia is not feasible in rural West Africa where most BU cases occur [2]. All patients included in
this study healed without changes in therapy (no change in antibiotics, no corticosteroids).
This strongly supports our suggested definition and suggests that cases in our study represent
true paradoxical reaction and not progressive disease secondary to antibiotic failure.
We found a 22% incidence of paradoxical reactions (2 consecutive increases after 1 initial
decrease and healing without surgery or a change in antimicrobial therapy), which is similar to
a previous study from Australia [9].
In our study, most paradoxical reactions occurred between week 8 and 12—slightly later
than the Australian study, where most paradoxical reactions occurred between week 3 and 10
Fig 1. Number of paradoxical reactions by weeks after starting treatment.
doi:10.1371/journal.pntd.0004594.g001
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[9,11]. In the case reports from Benin paradoxical reactions occurred between 12 and 409 days
after completion of antibiotic treatment [10].
Mycolactone, the exotoxin produced and secreted byM. ulcerans, has been proposed as the
major cause of immune suppression [28–32]. Perhaps, the period between week 8 and 12 in
which most paradoxical reactions occurred coincides with the elimination of mostM. ulcerans
organisms, with an arrest in the production and subsequently, a strong decrease in tissue con-
centration of mycolactone. The increase of the lesion then reflects an inflammatory response
against the microbes—or microbial antigens of dead bacilli—already present in tissue which
initially failed to elicit a host immune response [25–27,30].
We found several risk factors associated with paradoxical reactions. The incidence appeared
to increase in larger lesions. One explanation of this may be that smaller lesions heal before
eight weeks when most of the paradoxical reaction occurs. Another possibility is that larger
lesions have a higher bacterial load than small lesions. We showed that lesions localized on
trunk were significantly associated with paradoxical reaction, even when controlling for the
size of the lesion. More than 4 out 10 patients (44%) with lesion on the trunk had paradoxical
reaction compared to 24% and 17% for the upper limb and lower limb respectively. The
increased incidence of paradoxical reactions on the trunk might be due to a difference in local
immune responses and body temperature.
Table 1. Risk factors associated with paradoxical reactions.
Risk factor PR No PR OR (95%CI) p-value
Age mean (SD) 15.2 (12.5) 16.5 (13.4) N/A 0.529*
Gender n (%) Female 36 (24%) 117 (76%) 1
Male 16 (18%) 72 (88%) 0.72 (0.37–1.40) 0.416ǂ
WHO categoryn (%) CAT 1 7 (10%) 62 (90%) 1
CAT 2 36 (27%) 97 (73%) 3.29 (1.38–7.87) 0.007ǂ
CAT 3 9 (23%) 30 (77%) 2.66 (0.90–7.81) 0.076ǂ
site of lesion n (%) Lower limb 20 (17%) 97 (83%) 1
Upper limb 24 (24%) 76 (76%) 1.54 (0.79–2.94) 0.209ǂ
Trunk 8 (44%) 10 (56%) 3.88 (1.36–11.1) 0.011ǂ
Type of lesion n (%) Ulcerative 29 (20%) 113 (80%) 1
Non-ulcerative 23 (23%) 76 (76%) 1.18 (.64–2.19) 0.602ǂ
Vitamin D nmol/Lmean (SD) 66.5 (19.1) 68.3 (17.1) N/A 0.631*
3’UTR TGTG n (%) ins/ins 22 (31%) 48 (69%) 1
ins/del 4 (6%) 63 (94%) 0.14 (0.05–0.44) 0.001ǂ
del/del 1 (13%) 7 (87%) 0.44 (0.04–4.55) 0.494ǂ
D543N n (%) G/G 25 (21%) 96 (79%) 1
G/A 2 (8%) 23 (92%) 3.00 (0.66–13.51) 0.155ǂ
A/A 0 (0%) 0 (0%) N/A
INT4 n (%) G/G 21 (17%) 105 (83%) 1
G/C 5 (28%) 13 (72%) 1.56 (.55–4.43) 0.405ǂ
C/C 1 (100%) 0 (0%) N/A
5’(CA)n n (%) 200/200 9 (14%) 60 (86%) 1
200/other 17 (25%) 52 (75%) 2.18 (.90–5.30) 0.086ǂ
other/other 1 (13%) 7 (87%) 0.98 (.32–2.95) 0.975ǂ
* = t-test
ǂ = Binary logistic regression, PR = paradoxical reaction, OR = Odds ratio, CI = conﬁdence interval.
doi:10.1371/journal.pntd.0004594.t001
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Our study shows that paradoxical reactions were not significantly associated with patient
age or type of lesion. This finding contrasts with Australian patients in whom associations
between paradoxical reactions and age and edema were reported [9]. This might be due to dif-
ferences in the study populations. In affluent countries like Australia, with a steeper population
pyramid, BU mainly affects the elderly in Australia [31], while in West Africa, most patients
are children [32].
Paradoxical reactions were not associated with the white blood cell count or patients’ vital
parameters such as the temperature and the pulse rate. We argue that an increase of pulse, tem-
perature or white blood cell count is indicative of an additional disease or super-infection,
which should be further investigated. Whether paradoxical reactions were associated with ami-
noglycoside use, as has been shown for amikacin in Australia, could not be examined for strep-
tomycin use because all study participants had been exposed to this drug, for 4 or 8 weeks. One
might speculate that this effect seen in amikacin might in fact reflect a decrease in paradoxical
reactions by using antimicrobial drugs like macrolides that have been associated with
immuno-modulatory effects [33].
We also show for the first time that paradoxical reactions toM. ulcerans infection are associ-
ated with genetic factors. Carrying the homozygous ins/ins genotype of 3’UTR TGTG poly-
morphism in the SLC11A1 increases the risk of paradoxical reactions in BU. Earlier studies
have shown that genetic factors can influence the innate immune response to mycobacterial
antigens, such as infectious disease susceptibility genes, e.g., SLC11A1, HLA-DR, vitamin D3
receptor, and mannose binding protein [34,35]. In BU no associations were found with the
3’UTR TGTG ins/del polymorphism and developing BU [16]. However in tuberculosis, it was
reported that participants who were heterozygous for two SLC11A1 polymorphisms (INT4 and
3’UTR) were at highest risk of tuberculosis [35]. A meta-analysis [35] has shown that the
TGTG ins/ins 3’UTR genotype protected against tuberculosis, compared to the del/del geno-
type. We interpret our data such that the protective TGTG ins/ins 3’UTR genotype in the
SLC11A1 gene may induce a stronger immune response duringM. ulcerans infection. In turn,
this stronger immune response might increase the risk of paradoxical reactions once BU devel-
ops. It has been reported that genetic variation in SLC11A1 affects susceptibility to others
mycobacterial diseases such as leprosy and tuberculosis [35–37]. However, no study addressed
the genetic risk factor for paradoxical reaction in tuberculosis or leprosy.
In this study, we report for the first time that paradoxical reactions are not associated with
vitamin D level. Vitamin D deficiency has been found to be associated with susceptibility to
tuberculosis [38]. Very few studies address vitamin D and paradoxical reactions in tuberculosis.
Clearing of pathogens with anti-tuberculosis treatment and a delayed negative feedback on
macrophage activation due to low 1,25(OH)2D production from vitamin D deficiency can lead
to excessive granuloma formation and an exacerbated inflammatory response [39]. In our sam-
ple, the means of vitamin D level in patients with or without paradoxical reactions were
similar.
All included patients in this study healed without any change in therapy. In earlier studies
corticosteroids were used to treat paradoxical reactions [9,40,41]. We would indeed caution for
use of corticosteroids West Africa, as other infections like tuberculosis and strongyloidiasis
may worsen.
This study has some limitations. There are no standard definitions of paradoxical reactions
in BU that we could use to validate our definition. Our definition is clinical and did not include
histological aspects, which may lead to a lack of accuracy. However we believe that our cases
accurately represent paradoxical reactions since all patients healed without any additional ther-
apy. Secondly, we excluded co-infected patients with Buruli ulcer and HIV. This may have
reduced the incidence and severity [42].
Genetic Predisposition for Paradoxical Reactions in BU
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Paradoxical reactions are common in BU–and it is important that these should be differen-
tiated from antimicrobial treatment failure. These paradoxical reactions are associated with
trunk localization, larger lesions and certain polymorphisms in the SLC11A1 gene. There was
no apparent need to change therapy or add steroids.
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